Press release
Long-Term Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) should contact the Shareholders Foundation in connection with Investigation over potential Wrongdoing
An investigation on behalf of current long term investors in Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares.
Investors who are current long term investors in Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: NTLA stocks follows a lawsuit filed against Intellia Therapeutics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: NTLA stocks, concerns whether certain Intellia Therapeutics, Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the District of Massachusetts the plaintiff alleges that the defendants created the false impression that they possessed reliable information pertaining to the viability of NTLA-3001's development and eventual marketing, if approved, that Intellia's optimistic reports of timelines, including dosing and future studies of the drug, fell short of reality; the NTLA program was not viable or sustainable for Intellia because viral-based editing programs remained expensive and inefficient in comparison to then-existing non-viral delivery methods, that Intellia was not equipped to timely dose patients with NTLA-3001, maintain the drug's research and development, or even to maintain its full staff in light of the existing scientific landscape surrounding viral-based editing drugs, and that even if NTLA-3001 proved successful, the use of viral-based editing drugs is costly, inefficient, and poor mitigators of adverse effects in patients.
Those who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Long-Term Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) should contact the Shareholders Foundation in connection with Investigation over potential Wrongdoing here
News-ID: 4002140 • Views: …
More Releases from Shareholders Foundation, Inc.
Investigation announced for Long-Term Investors in shares of Neumora Therapeutic …
An investigation was announced over potential breaches of fiduciary duties by certain directors and officers of Neumora Therapeutics, Inc.
Investors who are current long term investors in Neumora Therapeutics, Inc. (NASDAQ: NMRA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: NMRA stocks follows a lawsuit filed against Neumora Therapeutics,…
Lawsuit filed for Investors who lost money with shares of Avis Budget Group, Inc …
An investor, who purchased shares of Avis Budget Group, Inc. (NASDAQ: CAR), filed a lawsuit over alleged violations of Federal Securities Laws by Avis Budget Group, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Avis Budget Group, Inc. (NASDAQ: CAR) have certain options and for certain investors are short and strict deadlines running. Deadline: June 24, 2025. NASDAQ: CAR investors should contact the Shareholders…
Long-Term investors in FMC Corporation (NYSE: FMC) shares should contact the Sha …
An investigation on behalf of current long-term investors in shares of FMC Corporation (NYSE: FMC) concerning potential breaches of fiduciary duties by certain directors and officers of FMC Corporation was announced.
Investors who are current long term investors in FMC Corporation (NYSE: FMC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Investigation announced for Long-Term Investors in shares of TransMedics Group, …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of TransMedics Group, Inc.
Investors who are current long term investors in TransMedics Group, Inc. (NASDAQ: TMDX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: TMDX stocks follows a lawsuit filed against TransMedics…
More Releases for Intellia
Genome Engineering Market will generate new growth opportunities 2022-2028 | The …
The Genome Engineering Market report aims to convey an inexpensive understanding of the business which has been analyzed by using primary and secondary research strategies. the main purpose of this Genome Engineering Market report is to supply an in-depth view and strategic analysis of the parent industry. The report examines each segment also as their respective sub-segments present within the market in an all-inclusive manner. The report provides a deep…
CRISPR Market 2022 Precise Outlook - Intellia Therapeutics, Inc., Integrated DNA …
The Global CRISPR Market Research Report Forecast 2022 - 2026 is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Market study provides comprehend CRISPR data that enhances the understanding, scope, and application of…
Genome Engineering Market to See Booming Growth 2021-2028 | Thermo Fisher Scient …
Overview:
Genome engineering, also known as genetic editing, gene manipulation, or genetic engineering, is basically a form of genetic engineering where DNA is introduced, inserted, deleted, or altered at the genetic level of an organism. It involves editing and modifying the genetic material of living organisms. Genome engineering technologies enable scientists to make changes in DNA, leading to changes in physical traits. In recent years, several approaches to genome editing have…
Hyperoxaluria Drug Market to Show Incredible Growth by 2028 || Major Players All …
DBMR has added a new report titled Hyperoxaluria Drug Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. Hyperoxaluria Drug Market report puts forward CAGR value fluctuations during the forecast period of 2021-2028 for the market. A market research analysis and estimations carried out in this marketing report aids businesses in gaining knowledge about what is…
CRISPR-CAS 9 Technology Market Revolutionary CAGR +20% by 2028 with AstraZeneca, …
CRISPR-CAS 9 Technology Market is projected to thrive $5 Bn at a CAGR +20% by the end of 2028.
CRISPR-Cas9 is a unique technology that enables geneticists and medical researchers to edit parts of the genome by removing, adding or altering sections of the DNA sequence. It is currently the simplest, most versatile and precise method of genetic manipulation and is therefore causing a buzz in the science world.
CRISPR-Cas9 was adapted…
Genome Editing Market | Caribou Biosciences, Inc., Sigma Aldrich Corporation, Sa …
Global Genome Editing Market: Overview
Also known as genome editing with engineered nucleases (GEEN), genome editing is a method of altering DNA within a cell in a safe manner. The technique is also used for removing, adding, or modifying DNA in the genome. By thus editing the genome, it is possible to change the primary characteristic features of an organism or a cell.
The global genome editing market can be segmented on…
